Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

BioScience Health Innovations (BHIC) EPS (Weighted Average and Diluted) (2023 - 2026)

BioScience Health Innovations has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$0.02 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) fell 300.0% to -$0.02 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$0.03 through Mar 2026, down 250.0% year-over-year, with the annual reading at $0.06 for FY2025, 500.0% up from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.02 for Q1 2026 at BioScience Health Innovations, roughly flat from -$0.02 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.01 in Q3 2024 and troughed at -$0.02 in Q4 2025.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$0.0 (2023), against an average of -$0.0.
  • Year-over-year, EPS (Weighted Average and Diluted) tumbled 326.58% in 2024 and then soared 875.4% in 2025.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.0 in 2023, then plummeted by 326.58% to -$0.0 in 2024, then plummeted by 312.5% to -$0.02 in 2025, then increased by 0.0% to -$0.02 in 2026.
  • Per Business Quant, the three most recent readings for BHIC's EPS (Weighted Average and Diluted) are -$0.02 (Q1 2026), -$0.02 (Q4 2025), and -$0.0 (Q3 2025).